Overview
Portfolio
More
Plumalley
New York, United States
Invests in early-stage medical breakthrough and frontier technology companies, focusing on Series A rounds and gender-diverse, STEM-focused founding teams.
Portfolio
25+
Employees
15+
Founded
2012
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
Global
Fund details
Funds
Venture Fund I
Vintage 2023 • $22.0M
Plum Alley Ventures Fund 2
Vintage 2025
Sources
Plumalley
Invests in early-stage medical breakthrough and frontier technology companies, focusing on Series A rounds and gender-diverse, STEM-focused founding teams.
Portfolio
25+
Employees
15+
Founded
2012
AUM
N/A
Funds
Venture Fund I · Vintage 2023 • $22.0M
Plum Alley Ventures Fund 2 · Vintage 2025
Showing 21 of 21 matched portfolio companies
Aclima provides a subscription‑based platform that combines mobile and fixed sensors to capture second‑by‑second concentrations of particulate matter, gases, greenhouse gases, and toxic compounds across urban to rural areas. The data are automatically calibrated, aggregated, and delivered via a cloud analytics suite with real‑time visualizations, trend tools, and API access for integration into regulatory, planning, and sustainability workflows.
50+
7K+Approximate amount of employees
Funding: $13.0M
Rough estimate of the amount of funding raised
Funding: $13.0M
Rough estimate of the amount of funding raised
AiFi is an AI retail platform that utilizes computer vision to create a 3D digital twin of physical retail spaces, enabling real-time analytics for inventory optimization and customer behavior insights. This technology allows retailers to enhance operational efficiency and improve the shopping experience by minimizing stockouts and optimizing store layouts.
Funding: $87.1M
Rough estimate of the amount of funding raised
Funding: $87.1M
Rough estimate of the amount of funding raised
Airprotein uses a proprietary microbial fermentation process to turn captured atmospheric CO₂ and renewable electricity into high‑quality protein powder. Its modular, closed‑loop bioreactors can be installed near food production sites, eliminating the need for land‑based feedstock and reducing water use while delivering a carbon‑negative protein source for manufacturers and food service operators.
Funding: $75.0M
Rough estimate of the amount of funding raised
Funding: $75.0M
Rough estimate of the amount of funding raised
The startup develops a robotics and data analytics platform that utilizes robots for pipe corrosion detection in the petrochemicals industry, employing 3D visualization tools and predictive analytics for inspection planning. This technology enables manufacturing companies to identify corrosion issues early, optimize resource allocation, and enhance operational efficiency, resulting in significant cost savings.
Funding: $17.5M
Rough estimate of the amount of funding raised
Funding: $17.5M
Rough estimate of the amount of funding raised
Ashvattha Therapeutics develops hydroxyl dendrimer-based nanomedicines that selectively target activated cells in inflamed tissues, addressing unmet medical needs in ophthalmology, neurology, and inflammatory diseases. This precision approach enhances treatment efficacy by ensuring that therapeutics are delivered specifically to areas of inflammation, minimizing off-target effects.
Funding: $149.2M
Rough estimate of the amount of funding raised
Funding: $149.2M
Rough estimate of the amount of funding raised
Biobot Analytics utilizes molecular technologies and AI to analyze wastewater, providing real-time data on population health threats such as viral outbreaks and substance use. This approach enables early detection of health trends, allowing public health officials to allocate resources effectively and implement proactive harm reduction strategies.
Funding: $27.6M
Rough estimate of the amount of funding raised
Funding: $27.6M
Rough estimate of the amount of funding raised
This company develops a non-invasive device for the early detection and monitoring of cardiovascular disease. Their patented diagnostic tool measures endothelial dysfunction, enabling healthcare professionals to diagnose the onset of disease and monitor treatment effectiveness.
Diligent Robotics develops Moxi, a hospital service robot equipped with artificial intelligence for mobile manipulation and social interaction, designed to assist clinical staff by autonomously fetching medications and supplies. This technology reduces the time healthcare workers spend on logistical tasks, allowing them to focus more on direct patient care, thereby improving patient satisfaction and operational efficiency.
Funding: $90.3M
Rough estimate of the amount of funding raised
Funding: $90.3M
Rough estimate of the amount of funding raised
Einride develops digital, electric, and autonomous shipping solutions that enhance the efficiency and sustainability of freight transportation. By integrating advanced connectivity and smart charging technologies, the company addresses the need for cleaner and safer logistics in the heavy-duty transport sector.
Funding: $652.3M
Rough estimate of the amount of funding raised
Funding: $652.3M
Rough estimate of the amount of funding raised
Evrnu utilizes its Nucycl® technology to convert discarded cotton textiles into a regenerated lyocell fiber that can be recycled multiple times, significantly reducing textile waste in landfills. This process addresses the environmental impact of the textile industry by providing a sustainable alternative to conventional raw materials like cotton and polyester.
Funding: $15.0M
Rough estimate of the amount of funding raised
Funding: $15.0M
Rough estimate of the amount of funding raised
One Health Company utilizes genomic testing and AI-driven precision medicine to identify targeted therapies for canine cancer, leveraging the largest proprietary cancer dataset from over 2,100 dogs. This approach addresses the high failure rate of traditional cancer treatments by providing veterinarians with data-driven insights to optimize treatment plans for individual dogs.
Funding: $15.0M
Rough estimate of the amount of funding raised
Funding: $15.0M
Rough estimate of the amount of funding raised
Gameto is a biotechnology company utilizing cell engineering to develop therapeutics for women's reproductive health, focusing on improving in vitro fertilization (IVF) and egg freezing processes. The company addresses significant gaps in fertility treatments and aims to enhance patient outcomes through its innovative platform.
Funding: $75.6M
Rough estimate of the amount of funding raised
Funding: $75.6M
Rough estimate of the amount of funding raised
Helaina utilizes a proprietary technology platform to replicate human lactoferrin, a bioactive protein that enhances iron utilization, supports immune health, and maintains gut function. By making this functional ingredient accessible, Helaina addresses the need for advanced nutritional solutions that promote overall health and vitality.
Funding: $83.0M
Rough estimate of the amount of funding raised
Funding: $83.0M
Rough estimate of the amount of funding raised
InnerPlant develops genetically engineered crops that emit optical signals to indicate stress from pathogens, nutrient deficiencies, or drought. This technology enables farmers to receive real-time, actionable insights, enhancing agricultural productivity and sustainability while reducing reliance on pesticides and waste.
Funding: $30.0M
Rough estimate of the amount of funding raised
Funding: $30.0M
Rough estimate of the amount of funding raised
Juvena Therapeutics utilizes an AI-driven platform to identify and engineer secreted proteins into biologic therapeutics that restore tissue homeostasis. The company addresses the dysregulation of protein signaling that leads to degenerative diseases, including myopathies and metabolic disorders.
Funding: $52.7M
Rough estimate of the amount of funding raised
Funding: $52.7M
Rough estimate of the amount of funding raised
KETOS offers a fully integrated water quality monitoring platform that utilizes IoT sensors to provide real-time data on over 30 water quality parameters, including heavy metals and nutrients. This technology replaces manual sampling, enabling water operators in industrial, agricultural, and municipal sectors to save time and ensure compliance with safety standards through automated reporting and predictive analytics.
Funding: $48.2M
Rough estimate of the amount of funding raised
Funding: $48.2M
Rough estimate of the amount of funding raised
Mammoth Biosciences develops CRISPR-Cas-based gene editing therapeutics and diagnostics to enable precise in vivo applications for serious diseases and molecular detection. Their technology addresses the challenges of gene delivery and expands testing capabilities, providing permanent solutions for unmet medical needs.
Funding: $374.8M
Rough estimate of the amount of funding raised
Funding: $374.8M
Rough estimate of the amount of funding raised
Markable Creators is an AI-powered visual discovery shopping engine that enables influencers to create personalized social shops and automate affiliate marketing tasks. By streamlining product linking and analytics, the platform helps creators save over two hours daily and increase their commissions by up to six times.
Funding: $21.7M
Rough estimate of the amount of funding raised
Funding: $21.7M
Rough estimate of the amount of funding raised
Phoenix Tailings builds a domestic rare earth refining ecosystem that extracts high‑purity rare earth metals and alloys from mining tailings and recycled streams using proprietary electrochemical and metallization technologies. By integrating AI‑driven automation and modular plant designs, the company delivers clean, scalable production to U.S. defense, automotive, medical, and advanced electronics customers, reducing reliance on foreign refining capacity.
Funding: $43.3M
Rough estimate of the amount of funding raised
Funding: $43.3M
Rough estimate of the amount of funding raised
Siren Biotechnology develops novel cancer treatments by integrating AAV gene therapy with cytokine immunotherapy into a single therapeutic modality. This approach aims to create a universal immuno-gene therapy effective against various solid tumors. The company is initially focusing on brain cancer as a key therapeutic area to establish this new treatment standard.
5+
3K+Approximate amount of employees
Funding: $25.6M
Rough estimate of the amount of funding raised
Funding: $25.6M
Rough estimate of the amount of funding raised
ThinkCERCA offers an AI‑enhanced ELAR curriculum for grades 3‑12 that automatically creates standards‑aligned lesson plans, scaffolds, and assessments. The platform includes Immersive Reader accessibility tools, embedded benchmark writing and ACT/SAT practice, and a unified analytics dashboard with SIS/LMS integration for data‑driven instruction.
Showing 4 of 4 unmatched portfolio companies